IST-MES1

Name: IST-MES1
Brand: Creative Bioarray

Cat.No.: CSC-6273W

Species: Homo sapiens (Human)

Source: Pleural Effusion

Morphology: grown as monolayer, epithelial-like

Culture Properties: Adherent

Inquire for Price

Specification
Scientific Data
Q & A
Customer Review

Cat.No.

CSC-6273W

Description

established from the pleural effusion of a 70- year- old Caucasian woman with pleural epithelioid mesothelioma

Species

Homo sapiens (Human)

Source

Pleural Effusion

Recommended Medium

DMEM + 10% FBS + 2mM L-Glutamine + 1% non-essential amino acids

Culture Properties

Adherent

Morphology

grown as monolayer, epithelial-like

Disease

Pleural Epithelioid Mesothelioma

Quality Control

Mycoplasma: negative in PCR assays
Viruses: PCR: HBV -, HCV -, HHV-8 -, HIV-1 -, HIV-2 -, HTLV-I/II -, MLV -, SMRV -

Storage and Shipping

ship in dry ice; store in liquid nitrogen

Synonyms

IST-Mes1; IST-MES-1; ISTMES1; Istituto Scientifico Tumori-Mesothelioma 1

Citation Guidance

If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

Identification of non-covalent inhibitors for the atypical peroxiredoxin PRDX5 as a therapeutic strategy in malignant pleural mesothelioma

bioRxiv | DOI | Paper 2026 | By Josep Monserrat, Floriane Montanari, Victor Laurent, Pierre-Benoit Ancey, Nicolas Jean, Cécilia Jeannu, Guimin Wang, Genshu You, Qiancheng Shen, Alice Mac Kain, Yacine Bareche, Loïc Herpin, Nadia Jeremiah, Roberta Codato, Alberto Romagnoni, Alex J. Cornish, Ekaterina Rozhavskaya, Lucia Pattarini, Constance Petit, Pierre-Joachim Zindy, Jinal Shukla, Sylvie Gomez, MOSAIC Consortium, Markus Eckstein, Almoatazbellah Youssef, Ulrich Keilholz, Markus Morkel, Krisztian Homicsko, Chiara Saglietti, Leilei Shi, Jian Zhang, Elodie Pronier

Background

This bioRxiv preprint identifies peroxiredoxin 5 (PRDX5) as a subtype-specific vulnerability in malignant pleural mesothelioma (MPM). Using MOSAIC single-cell and spatial transcriptomics, PRDX5 is upregulated in epithelioid MPM and correlates with resistance to oxidative/nitrosative stress. Machine-learning-guided pocket detection and virtual screening of 3.6 million compounds followed by biochemical validation yielded 36 non-covalent PRDX5 inhibitors, including sub-micromolar hits. The study nominates PRDX5 as a therapeutic target and provides chemical starting points for redox-modulating precision oncology in MPM.

Key Findings

PRDX5 is significantly upregulated in epithelioid malignant pleural mesothelioma (MPM) compared with sarcomatoid and biphasic subtypes, validated in an independent cohort where 97% of tumors expressed PRDX5 in >50% of cells and 73% showed moderate-to-strong staining. MPM cell lines resist peroxynitrite and H2O2 more than healthy mesothelial cells, correlating with basal PRDX5 expression. PRDX5-positive malignant cells are enriched for hypoxia, ROS detoxification, and RNS metabolism signatures, particularly in tumor cores. Using AlloDeep/AlloTango, the authors identified three putative allosteric pockets (G85, alpha3, alpha5) and virtually screened 3.6 million compounds. Biochemical testing of 452 candidates yielded 36 non-covalent inhibitors (8% hit rate), including 13 potent and 23 weakly active hits. G85 and alpha3 leads showed IC50 values of 4.46 µM and 9.81 µM, respectively, with an azetidine-containing scaffold. This establishes PRDX5 as a subtype-specific MPM target and provides new chemical tools for redox-modulating cancer therapy.

Contribution

Creative Bioarray provided the human malignant pleural mesothelioma cell lines IST-MES-1 and IST-MES-2, which were used for PRDX5 target validation, oxidative/nitrosative stress sensitivity assays, and protein expression analysis. These cell models were essential for confirming PRDX5-mediated stress resistance and supporting the therapeutic rationale.